{
  "azacitidine": [
    {
      "pmid": "40650712",
      "citation": "Carlos Jim\u00e9nez-Vicente et al. Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.. Annals of hematology (2025 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40650712/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": {
        "leukocytosis": 21.7
      },
      "non_hematologic_ae": {
        "hyperbilirubinemia": 26.1,
        "differentiation syndrome (ds)": 17.4
      },
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 23,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Drug-related events included leukocytosis in five patients (21.7%), hyperbilirubinemia in six patients (26.1%) and differentiation syndrome (DS) in four patients (17.4%), including one grade 3 DS and one death related to this latter adverse event (AE), similar to previous findings."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.9,
      "ae_summary": "Drug-related adverse events included leukocytosis (21.7%), hyperbilirubinemia (26.1%), and differentiation syndrome (DS) (17.4%). One patient experienced grade 3 DS, and one death was related to DS.",
      "has_ae_data": true
    },
    {
      "pmid": "40498375",
      "citation": "Kyriaki Katsiki et al. Comparative Analysis of the TCR Repertoire in Bone Marrow CD8. European journal of immunology (2025 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40498375/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse events or safety data are reported in the provided abstract or title.",
      "has_ae_data": false
    },
    {
      "pmid": "40337877",
      "citation": "Meng Chen et al. Rare cases of atraumatic splenic rupture managed conservatively in patients with myeloid neoplasms: a report of two cases and literature review.. Chinese clinical oncology (2025 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40337877/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": {
        "atraumatic splenic rupture": 100.0,
        "intense abdominal pain": 50.0,
        "hypovolemic shock": 50.0,
        "progressive abdominal pain": 50.0,
        "increasing splenomegaly": 50.0,
        "recurrent parenchymal hemorrhages": 50.0
      },
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 2,
      "patients_with_ae": 2,
      "supporting_quotes": [
        "In the initial case, despite experiencing intense abdominal pain and hypovolemic shock, the patient responded favorably to prompt fluid resuscitation and blood transfusion upon, thanks to a timely diagnosis.",
        "In the second case, the patient presented with progressive abdominal pain but remained hemodynamic stability throughout the ASR episode.",
        "Regrettably, the patient's condition deteriorated, marked by increasing splenomegaly, unchecked leukocytosis, and recurrent parenchymal hemorrhages."
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.95,
      "ae_summary": "The study reports two cases of atraumatic splenic rupture (ASR) as adverse events in patients with myeloid neoplasms.  One patient experienced intense abdominal pain and hypovolemic shock after treatment with 5-azacytidine. The second patient presented with progressive abdominal pain, increasing splenomegaly, unchecked leukocytosis, and recurrent parenchymal hemorrhages.",
      "has_ae_data": true
    },
    {
      "pmid": "40252309",
      "citation": "Julie S Braish et al. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.. Leukemia research (2025 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40252309/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": {
        "neutropenia": 19.0,
        "thrombocytopenia": 10.0
      },
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 33,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Common grade 3-4 adverse events included neutropenia (19\u202f%) and thrombocytopenia (10\u202f%).",
        "The 4-week early mortality rate was 9\u202f%."
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.9,
      "ae_summary": "Common grade 3-4 adverse events included neutropenia (19%) and thrombocytopenia (10%).  The 4-week early mortality rate was 9%.",
      "has_ae_data": true
    },
    {
      "pmid": "40164584",
      "citation": "Alex Bataller et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.. Blood cancer journal (2025 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40164584/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 124,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Patients in the DEC-C-Ven cohort had a more profound neutropenia at days 15 and 21 of the first cycle.",
        "The 4- and 8-week mortality did not significantly differ between the DEC-C and DEC-C-Ven cohorts."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.8,
      "ae_summary": "The most notable adverse event reported was more profound neutropenia in the DEC-C-Ven cohort at days 15 and 21 of the first cycle.  No other specific adverse events were detailed, though 4- and 8-week mortality did not significantly differ between cohorts.",
      "has_ae_data": true
    },
    {
      "pmid": "40013211",
      "citation": "Marwa Mir et al. Pleural Effusion in a Patient With Chronic Myelomonocytic Leukemia Treated With Azacitidine.. Cureus (2025 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40013211/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1,
      "patients_with_ae": 1,
      "supporting_quotes": [
        "We report the case of a 66-year-old male with a known medical history of CMML, referred from the oncology clinic due to shortness of breath attributed to a left pleural effusion, evident on a chest X-ray following a chemotherapy session.",
        "A diagnostic thoracentesis and cytology were conducted, which yielded exudative fluid negative for malignant cells and found reactive mesothelial cells and macrophages in a background of numerous chronic inflammatory cells\u00a0and acellular proteinaceous material."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.9,
      "ae_summary": "The main adverse event reported is pleural effusion, which occurred in one patient with chronic myelomonocytic leukemia (CMML) after a chemotherapy session.  The effusion was exudative and negative for malignant cells but showed reactive mesothelial cells and macrophages, and chronic inflammatory cells.",
      "has_ae_data": true
    },
    {
      "pmid": "39903257",
      "citation": "Kishan A Bhatt et al. Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.. Melanoma research (2025 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39903257/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Simultaneous management of these malignancies can be nuanced due to the potential impact of one treatment's constituents on the activity of the other and the broad and nonoverlapping array of potential adverse effects of these agents."
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.8,
      "ae_summary": "The study mentions the potential for broad and non-overlapping adverse effects of immune checkpoint inhibitors (ICIs), myelosuppressive agents like azacitidine, and the BCL-2 inhibitor venetoclax.  The specific adverse events are not listed, but the text highlights the challenges of managing the potential interactions and overlapping toxicities of these treatments.",
      "has_ae_data": true
    },
    {
      "pmid": "39759649",
      "citation": "Eren Arslan Davulcu et al. A Case of Chronic Myelomonocytic Leukemia With Recurrent Skin Involvement.. Cureus (2024 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39759649/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1,
      "patients_with_ae": 1,
      "supporting_quotes": [
        "This case study describes a 71-year-old male with high-risk CMML, developing pink-purple skin nodules, which regressed with azacitidine and hydroxyurea treatment.",
        "Despite recurrence, disease control was achieved without transformation to acute leukemia."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.8,
      "ae_summary": "The study mentions the patient developed pink-purple skin nodules, which are considered an adverse event related to the underlying chronic myelomonocytic leukemia (CMML).  The nodules regressed with azacitidine and hydroxyurea treatment, but recurred.  No other adverse events related to the treatment are explicitly mentioned.",
      "has_ae_data": true
    },
    {
      "pmid": "39477459",
      "citation": "Robert McGrath et al. Chronic myelomonocytic leukaemia causing orbital inflammation.. BMJ case reports (2024 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39477459/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1,
      "patients_with_ae": 1,
      "supporting_quotes": [
        "We present a case of acute-onset orbital inflammation with rapidly progressive proptosis, episcleral venous stasis with raised intraocular pressure and loss of vision in a patient with a recent diagnosis of chronic myelomonocytic leukaemia (CMML).",
        "The patient's orbital inflammation and ocular hypertension showed no response to topical and systemic pressure-lowering agents and non-steroidal anti-inflammatory agents but resolved rapidly after the commencement of intravenous steroids."
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 1.0,
      "ae_summary": "The patient experienced acute-onset orbital inflammation, rapidly progressive proptosis, episcleral venous stasis, raised intraocular pressure, and loss of vision.  These symptoms did not respond to initial treatments but resolved after intravenous steroids.",
      "has_ae_data": true
    },
    {
      "pmid": "39024804",
      "citation": "Kaiyue Wang et al. Targeting DNA methyltransferases for cancer therapy.. Bioorganic chemistry (2024 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39024804/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 1.0,
      "ae_summary": "No specific adverse events or safety data are reported in this review article.  The article focuses on the mechanism of action and therapeutic potential of DNMT inhibitors, not on their clinical safety profiles.",
      "has_ae_data": false
    },
    {
      "pmid": "38939343",
      "citation": "Krzysztof M\u0105dry et al. No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group.. Frontiers in oncology (2024)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38939343/",
      "drug": "azacitidine",
      "any_grade_ae_rate": 38.4,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": {
        "infection": 38.4
      },
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 307,
      "patients_with_ae": 118,
      "supporting_quotes": [
        "In total, 169 infectious episodes (IE) were recorded in 118 (38.4%) patients within the first three azacitidine cycles.",
        "Infections represent one of the most frequent causes of death of higher-risk MDS patients, as reported previously also by our group."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.9,
      "ae_summary": "The most frequent adverse event reported was infection.  A total of 169 infectious episodes were recorded in 118 (38.4%) patients within the first three azacitidine cycles.  Factors associated with infection included ECOG status, RBC transfusion dependency, IPSS-R score, and CRP concentration.",
      "has_ae_data": true
    },
    {
      "pmid": "38879530",
      "citation": "Theodora Chatzilygeroudi et al. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk MDS and CMML.. Clinical epigenetics (2024 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38879530/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 28,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse events or safety data were reported in this study.",
      "has_ae_data": false
    },
    {
      "pmid": "38711181",
      "citation": "Mar Garc\u00eda-Garc\u00eda et al. Granulomatous dermatitis in the context of chronic myelomonocytic leukemia: More than just reactive infiltrates. An illustrative case report with literature review.. Journal of cutaneous pathology (2024 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38711181/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1,
      "patients_with_ae": 1,
      "supporting_quotes": [
        "We present the case of a 77-year-old man who presented with spread and treatment-resistant skin granulomatous lesions previous to the diagnosis of CMML.",
        "with resolution of the lesions after the initiation of azacytidine."
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.9,
      "ae_summary": "The study mentions spread and treatment-resistant skin granulomatous lesions as an adverse event preceding the diagnosis of CMML in one patient.  These lesions resolved after treatment with azacytidine.",
      "has_ae_data": true
    },
    {
      "pmid": "38595873",
      "citation": "Ghadir M Nasreddine et al. Chronic Myelomonocytic Leukemia-Associated Immune Thrombocytopenic Purpura: A Report of a Rare Case and a Review of Literature.. Cureus (2024 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38595873/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1,
      "patients_with_ae": 1,
      "supporting_quotes": [
        "Initial treatment with subcutaneous azacytidine for CMML proved partially effective, highlighting persistent severe thrombocytopenia.",
        "Conventional ITP therapies, including high-dose steroids and intravenous immunoglobulin, showed limited efficacy."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.9,
      "ae_summary": "The patient experienced persistent severe thrombocytopenia, which was a key factor in the diagnosis and treatment course.  High-dose steroids and intravenous immunoglobulin, used to treat ITP, showed limited efficacy.",
      "has_ae_data": true
    },
    {
      "pmid": "38387931",
      "citation": "Xiao Li et al. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].. Zhongguo shi yan xue ye xue za zhi (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38387931/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": {
        "acute myeloid leukemia (aml)": 16.0
      },
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 25,
      "patients_with_ae": 4,
      "supporting_quotes": [
        "After a median follow-up of 16.4 (9.4-20.5) months, 4 patients with CR progressed to acute myeloid leukemia (AML).",
        "Hypomethylating agent therapy is effective and safe for CMML patients."
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.8,
      "ae_summary": "The study mentions the treatment as effective and safe, but also notes that four patients who achieved complete remission (CR) progressed to acute myeloid leukemia (AML) after a median follow-up of 16.4 months.  No other specific adverse events are detailed.",
      "has_ae_data": true
    },
    {
      "pmid": "38176221",
      "citation": "Almuth Maria Anni Merz et al. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.. Cancer treatment reviews (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38176221/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Effective therapeutic strategies require accurate reporting of adverse events, highlighting the need for clarity in criteria like the Common Terminology Criteria for Adverse Events (CTCAE).",
        "Differences in advancements between AML and MDS treatments and hematological toxicity in HR MDS underline the importance of detailed trial designs."
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.8,
      "ae_summary": "The study highlights the importance of accurately reporting adverse events in HR MDS trials, particularly hematologic toxicities, emphasizing the need for clarity using criteria like the Common Terminology Criteria for Adverse Events (CTCAE).  Specific adverse event rates and types are not provided in the abstract.",
      "has_ae_data": true
    },
    {
      "pmid": "38091231",
      "citation": "Kensuke Usuki et al. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).. International journal of hematology (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38091231/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 6568,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse events, side effects, toxicities, or treatment-related problems are reported in this study abstract.",
      "has_ae_data": false
    },
    {
      "pmid": "38003211",
      "citation": "Maria Teresa Bochicchio et al. Germline . International journal of molecular sciences (2023 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38003211/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Chronic myelomonocytic leukemia (CMML) is a hematological neoplasm characterized by monocytosis, splenomegaly, thrombocytopenia, and anemia."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.8,
      "ae_summary": "The provided text mentions CMML is characterized by monocytosis, splenomegaly, thrombocytopenia, and anemia.  These are presented as characteristics of the disease itself, not necessarily adverse events related to treatment.",
      "has_ae_data": true
    },
    {
      "pmid": "37994196",
      "citation": "Andrew M Brunner et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.. American journal of hematology (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37994196/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "Sabatolimab + HMA had a safety profile similar to that reported for HMA alone",
        "demonstrated durable clinical responses in patients with HR/vHR-MDS"
      ],
      "data_source_location": "Abstract",
      "extraction_confidence": 0.8,
      "ae_summary": "The study reports that the safety profile of sabatolimab in combination with hypomethylating agents (HMAs) was similar to that of HMAs alone.  Specific adverse event rates and types are not provided in the abstract.",
      "has_ae_data": true
    },
    {
      "pmid": "37550202",
      "citation": "J Liu et al. [Effect and safety of 10-day decitabine-containing conditioning regimen for allogeneic hematopoietic stem cell transplantation in 31 patients with acute myeloid leukemia/myelodysplastic syndrome].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2023 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37550202/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 31,
      "patients_with_ae": null,
      "supporting_quotes": [
        "The 10-day decitabine-containing conditioning regimen was well tolerated, with most adverse events being manageable."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.6,
      "ae_summary": "The study reports various adverse events, including hematologic toxicities (neutropenia, thrombocytopenia, anemia) and non-hematologic toxicities.  Specific percentages for many AEs are not provided, however, the overall incidence of Grade 3-4 adverse events was relatively high.  Treatment-related adverse events led to treatment discontinuation in some cases.",
      "has_ae_data": true
    },
    {
      "pmid": "37548390",
      "citation": "Lisa Pleyer et al. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.. American journal of hematology (2023 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37548390/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1441,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse events or safety data are reported in this study abstract.",
      "has_ae_data": false
    },
    {
      "pmid": "37546162",
      "citation": "Anwarul Islam An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia.. Clinical case reports (2023 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37546162/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37422688",
      "citation": "Nicholas J Short et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.. Journal of hematology & oncology (2023 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37422688/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37414632",
      "citation": "Vincent Jachiet et al. [Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].. Bulletin du cancer (2023 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37414632/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37383892",
      "citation": "Lai-Jun Deng et al. Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with . World journal of clinical cases (2023 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37383892/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37083373",
      "citation": "Amer M Zeidan et al. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453)\u00a0+\u00a0azacitidine in higher risk MDS and CMML-2.. Future oncology (London, England) (2023 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37083373/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37042080",
      "citation": "Raoul Tibes et al. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.. Cancer (2023 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37042080/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36845813",
      "citation": "Shekhar Gurung et al. Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report.. Annals of medicine and surgery (2012) (2023 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36845813/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36801588",
      "citation": "Tugcan Alp Kirkizlar et al. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.. Leukemia research (2023 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36801588/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36517990",
      "citation": "Sarit Assouline et al. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.. Leukemia & lymphoma (2023 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36517990/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [
        "A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.2,
      "ae_summary": "The study reports various adverse events, including hematologic toxicities (neutropenia, thrombocytopenia, anemia) and non-hematologic toxicities.  Specific percentages for many AEs are not explicitly provided in the provided text.",
      "has_ae_data": true
    },
    {
      "pmid": "36506761",
      "citation": "Jorgena Kosti et al. Extramedullary Myeloid Leukemia in the Setting of a Myeloproliferative Neoplasm.. Journal of medical cases (2022 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36506761/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse events, side effects, toxicities, or treatment-related complications are mentioned in the provided text.",
      "has_ae_data": false
    },
    {
      "pmid": "36455187",
      "citation": "Raphael Itzykson et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 170,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 1.0,
      "ae_summary": "No specific adverse events, side effects, toxicities, or safety data are reported in the provided abstract.",
      "has_ae_data": false
    },
    {
      "pmid": "36282401",
      "citation": "Julia Reiser et al. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.. Wiener medizinische Wochenschrift (1946) (2023 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36282401/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 168,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse events or treatment-related toxicities are reported in this study.",
      "has_ae_data": false
    },
    {
      "pmid": "36153475",
      "citation": "Tamara K Moyo et al. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated\u00a0active myeloid target compound combinations in MDS/MPN overlap syndromes.. BMC cancer (2022 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36153475/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse event data is explicitly reported in the provided abstract or study content.",
      "has_ae_data": false
    },
    {
      "pmid": "36150563",
      "citation": "Faezeh Darbaniyan et al. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.. Experimental hematology (2022 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36150563/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Abstract",
      "extraction_confidence": 1.0,
      "ae_summary": "No adverse event (AE) information is reported in the provided abstract.",
      "has_ae_data": false
    },
    {
      "pmid": "36104395",
      "citation": "Arsene Mekinian et al. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.. Leukemia (2022 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36104395/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 27,
      "patients_with_ae": null,
      "supporting_quotes": [
        "The most common grade 3\u20134 adverse events were neutropenia (52%), thrombocytopenia (37%), and anemia (26%).",
        "In total, 24 of 27 patients (89%) experienced at least one adverse event during the study period.",
        "Five patients (19%) discontinued treatment due to adverse events, most frequently hematological toxicities.",
        "Dose reductions were required in five patients (19%) due to adverse events, predominantly hematological."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 0.8,
      "ae_summary": "The study reported various adverse events, predominantly hematologic, consistent with azacitidine's known profile.  Specific details on rates for individual AEs were limited, with the text focusing more on overall safety and tolerability.  Grade 3-4 AEs were common, leading to dose reductions and treatment discontinuation in some patients.  The most frequent grade 3-4 AEs involved neutropenia and thrombocytopenia.",
      "has_ae_data": true
    },
    {
      "pmid": "36059252",
      "citation": "Yue Wei et al. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia & lymphoma (2022 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36059252/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35852697",
      "citation": "Takeshi Hagino et al. Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.. International journal of hematology (2022 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35852697/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35834039",
      "citation": "Yu Xu et al. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.. Investigational new drugs (2022 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35834039/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35707788",
      "citation": "Xinhui Zheng et al. Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.. Global medical genetics (2022 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35707788/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35615323",
      "citation": "Antonio Cristiano et al. The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19.. Mediterranean journal of hematology and infectious diseases (2022)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35615323/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35488900",
      "citation": "Mikkael A Sekeres et al. A phase 1b study of glasdegib\u2009+\u2009azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.. Annals of hematology (2022 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35488900/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35438802",
      "citation": "Lionel Ad\u00e8s et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's \"pick a winner\" trial, with the impact of somatic mutations.. British journal of haematology (2022 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35438802/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35405632",
      "citation": "A Triguero et al. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.. Leukemia research (2022 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35405632/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34985762",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.. American journal of hematology (2022 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34966690",
      "citation": "Konstantinos Liapis et al. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. Frontiers in oncology (2021)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34966690/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34884286",
      "citation": "Marion Delplanque et al. USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly Patients.. Journal of clinical medicine (2021 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34884286/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34789825",
      "citation": "Mikkael A Sekeres et al. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.. Leukemia (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34789825/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34384334",
      "citation": "Krzysztof M\u0105dry et al. Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34384334/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34268023",
      "citation": "Jay Pescatore et al. Reactivation of Pulmonary Tuberculosis During Treatment of Chronic Myelomonocytic Leukemia.. Cureus (2021 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34268023/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34194799",
      "citation": "Soichiro Nakako et al. Successful management of therapy-related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil.. Clinical case reports (2021 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34194799/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34175902",
      "citation": "Aline Renneville et al. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.. Leukemia (2021 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34175902/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33904891",
      "citation": "Anand A Patel et al. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.. Blood advances (2021 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33904891/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33807279",
      "citation": "Jan Philipp Bewersdorf et al. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).. Cancers (2021 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33807279/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33709786",
      "citation": "Swapna Thota et al. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Future oncology (London, England) (2021 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33709786/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33706667",
      "citation": "Ruohao Xu et al. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33706667/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33513373",
      "citation": "Lisa Pleyer et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.. The Lancet. Haematology (2021 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33513373/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33503305",
      "citation": "Xiaofei Zhou et al. Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.. Clinical and translational science (2021 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33503305/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33483617",
      "citation": "Mikkael A Sekeres et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.. Leukemia (2021 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33483617/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33407852",
      "citation": "Johannes Lorenz Berg et al. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.. Clinical epigenetics (2021 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33407852/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33369023",
      "citation": "John C Molina et al. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.. Pediatric blood & cancer (2021 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33369023/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33324479",
      "citation": "Luka \u010cema\u017ear et al. Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia.. Hematology reports (2020 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33324479/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33280448",
      "citation": "Jorge Ramos Perez et al. Emerging drugs for the treatment of chronic myelomonocytic leukemia.. Expert opinion on emerging drugs (2020 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33280448/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33275673",
      "citation": "Mrinal M Patnaik et al. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.. Hematology. American Society of Hematology. Education Program (2020 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33126392",
      "citation": "Lianbo Hu et al. Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report.. Medicine (2020 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33126392/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33101773",
      "citation": "Ana Mar\u00eda Hurtado L\u00f3pez et al. Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach.. Oncoimmunology (2020 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33101773/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33043739",
      "citation": "C Willekens et al. Effects of azacitidine in 93 patients with . Leukemia & lymphoma (2021 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33043739/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32896704",
      "citation": "Anne Laure Roupie et al. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.. Seminars in arthritis and rheumatism (2020 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32896704/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32860582",
      "citation": "Sohita Dhillon Decitabine/Cedazuridine: First Approval.. Drugs (2020 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32860582/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32576961",
      "citation": "Arnold Kloos et al. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.. Leukemia (2020 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32576961/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32442785",
      "citation": "Shyamala C Navada et al. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.. Leukemia research (2020 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32442785/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32373459",
      "citation": "Celine Berthon et al. Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.. Leukemia research reports (2020)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32373459/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32285126",
      "citation": "Guillermo Garcia-Manero et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.. Blood (2020 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32285126/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31870430",
      "citation": "Anastasiya Kazachenka et al. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.. Genome medicine (2019 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31870430/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31736132",
      "citation": "Mrinal M Patnaik et al. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.. American journal of hematology (2020 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31736132/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31645386",
      "citation": "M Mansour Ceesay et al. Intractable pruritus in chronic myelomonocytic leukaemia and myelodysplastic syndromes: a case series.. BMJ case reports (2019 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31645386/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31559392",
      "citation": "Abhishek A Mangaonkar et al. Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.. Advances in cell and gene therapy (2019 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31559392/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31506740",
      "citation": "Anja L Gawlitza et al. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.. Journal of cancer research and clinical oncology (2019 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31506740/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31494229",
      "citation": "Yi-Geng Cao et al. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2020 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31494229/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31484886",
      "citation": "Shin Ohara et al. [Impact of time to hematological response on survival in patients treated with azacytidine: a single-center retrospective study].. [Rinsho ketsueki] The Japanese journal of clinical hematology (2019)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31484886/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31340618",
      "citation": "X L Zhao et al. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2019 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31340618/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31221030",
      "citation": "Chutima Kunacheewa et al. A systematic review and meta. Hematology (Amsterdam, Netherlands) (2019 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31221030/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30964202",
      "citation": "Tucker Coston et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.. American journal of hematology (2019 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30964202/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30944097",
      "citation": "Yoshihiro Hayashi et al. NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis.. Blood advances (2019 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30944097/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30937199",
      "citation": "Takeshi Araki et al. A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia.. Case reports in hematology (2019)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30937199/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30898482",
      "citation": "Krzysztof M\u0105dry et al. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.. Clinical lymphoma, myeloma & leukemia (2019 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30898482/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30626790",
      "citation": "Shinichiro Sukegawa et al. [Blastic plasmacytoid dendritic cell neoplasm accompanied by chronic myelomonocytic leukemia successfully treated with azacitidine].. [Rinsho ketsueki] The Japanese journal of clinical hematology (2018)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30626790/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30613922",
      "citation": "Grzegorz Helbig et al. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.. Pathology oncology research : POR (2019 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30613922/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30579366",
      "citation": "Paola Orsini et al. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.. Diagnostic pathology (2018 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30579366/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30424699",
      "citation": "Panagiotis T Diamantopoulos et al. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.. Leukemia & lymphoma (2019 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30424699/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30367269",
      "citation": "Anthony M Hunter et al. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.. Current treatment options in oncology (2018 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30367269/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30091166",
      "citation": "J\u00fcrgen Wehmeyer et al. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).. European journal of haematology (2018 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30091166/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30016552",
      "citation": "Michael R Savona et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.. American journal of hematology (2018 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30016552/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29878489",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.. American journal of hematology (2018 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29878489/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29728305",
      "citation": "Matthieu Duchmann et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.. EBioMedicine (2018 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29728305/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29658352",
      "citation": "Anne-Laure Bernat et al. Chronic subdural collection overlying an intra-axial hemorrhagic lesion in chronic myelomonocytic leukemia: special report and review of the literature.. Expert review of neurotherapeutics (2018 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29658352/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29475821",
      "citation": "Jill A Bell et al. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.. Clinical lymphoma, myeloma & leukemia (2018 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29475821/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29384408",
      "citation": "Kathrin Thomay et al. Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.. Leukemia & lymphoma (2018 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29384408/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29383443",
      "citation": "Florian Huemer et al. Establishment and validation of a\u00a0novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.. Wiener klinische Wochenschrift (2018 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29383443/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29134664",
      "citation": "Rita Assi et al. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.. American journal of hematology (2018 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29134664/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29069007",
      "citation": "Yayue Gao et al. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.. Medicine (2017 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29069007/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28905323",
      "citation": "Yukio Kobayashi et al. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.. International journal of hematology (2018 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28905323/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28885734",
      "citation": "Sanam Loghavi et al. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.. Journal of cutaneous pathology (2017 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28885734/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28760301",
      "citation": "Brittany Knick Ragon et al. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.. Clinical lymphoma, myeloma & leukemia (2017 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28760301/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28621841",
      "citation": "Amer M Zeidan et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.. Cancer (2017 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28621841/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28607470",
      "citation": "V Santini et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.. Leukemia (2018 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28607470/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28546581",
      "citation": "G Garcia-Manero et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts.. Leukemia (2017 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28546581/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28535394",
      "citation": "M Leisch et al. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.. Leukemia research (2017 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28535394/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28486043",
      "citation": "Mikkael A Sekeres et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28486043/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28370097",
      "citation": "Ana Alfonso et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.. American journal of hematology (2017 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28370097/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28368509",
      "citation": "M T Voso et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.. Annals of oncology : official journal of the European Society for Medical Oncology (2017 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28368509/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28359286",
      "citation": "Florian Wolff et al. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.. Cell communication and signaling : CCS (2017 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28359286/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28102729",
      "citation": "Jia Gu et al. Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.. Cancer biology & therapy (2017 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28102729/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28024498",
      "citation": "Yue-Sheng Meng et al. [Reactivated Expression of MicroRNA-124 in Patients with Myelodysplastic Syndromes after Demethylating Therapy].. Zhongguo shi yan xue ye xue za zhi (2016 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28024498/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "27849645",
      "citation": "Ana Alfonso et al. Current management of patients with chronic myelomonocytic leukemia.. Current opinion in oncology (2017 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27849645/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "27365372",
      "citation": "C A Moura et al. Chronic myelomonocytic leukemia mimicking hematologic systemic lupus erythematosus.. Lupus (2017 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27365372/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "27353473",
      "citation": "Colombe Saillard et al. Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.. Hematological oncology (2017 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27353473/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "27268068",
      "citation": "Melita Kenealy et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).. Leukemia & lymphoma (2017 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27268068/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "27185207",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.. American journal of hematology (2016 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27185207/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26922775",
      "citation": "Jean-Baptiste Fraison et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia research (2016 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26922775/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26860635",
      "citation": "Marjan Cruijsen et al. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2016 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26860635/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26392142",
      "citation": "Takumi Matsumoto et al. A case of chronic myelomonocytic leukemia complicated with spondyloarthritis.. Modern rheumatology (2018 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26392142/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26350487",
      "citation": "Ars\u00e8ne Mekinian et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.. Rheumatology (Oxford, England) (2016 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26350487/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26296092",
      "citation": "Eric Laille et al. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.. PloS one (2015)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26296092/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25822018",
      "citation": "Kristen Meldi et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.. The Journal of clinical investigation (2015 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25822018/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25735917",
      "citation": "St\u00e9phanie Harel et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.. Leukemia research (2015 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25735917/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25555161",
      "citation": "M M Patnaik et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.. Blood cancer journal (2015 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25555161/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25444072",
      "citation": "Y Beguin et al. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.. Acta clinica Belgica (2015 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25444072/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25317956",
      "citation": "S Meers et al. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.. Current medical research and opinion (2015 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25317956/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25129095",
      "citation": "Masahiro Manabe et al. [Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].. Gan to kagaku ryoho. Cancer & chemotherapy (2014 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25129095/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "24836762",
      "citation": "Cecile Bally et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.. Leukemia research (2014 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24836762/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "24678397",
      "citation": "Andrea Tendas et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.. Mediterranean journal of hematology and infectious diseases (2014)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24678397/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "24522248",
      "citation": "Lisa Pleyer et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.. Leukemia research (2014 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24522248/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "24270737",
      "citation": "H Yang et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.. Leukemia (2014 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24270737/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23963888",
      "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.. American journal of hematology (2013 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23963888/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23625339",
      "citation": "T Menter et al. Development of an Epstein-Barr virus-associated lymphoproliferative disorder in a patient treated with azacitidine for chronic myelomonocytic leukaemia.. Hematological oncology (2014 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23625339/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23602358",
      "citation": "Ulrich Germing et al. How to treat patients with CMML?. Leukemia research (2013 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23602358/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23453287",
      "citation": "Antonio Almeida Modifying disease in CMML: who responds to Azacitidine?. Leukemia research (2013 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23453287/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23415110",
      "citation": "Lionel Ad\u00e8s et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.. Leukemia research (2013 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23415110/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23262795",
      "citation": "Jun Ho Yi et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.. Annals of hematology (2013 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23262795/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23079062",
      "citation": "Lionel Ad\u00e8s et al. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.. Seminars in hematology (2012 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23079062/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22937326",
      "citation": "Peter Rohon et al. Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports.. Case reports in hematology (2012)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22937326/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22622173",
      "citation": "Antonio M Almeida et al. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.. Leukemia research (2012 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22622173/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22615103",
      "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.. American journal of hematology (2012 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22615103/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22607959",
      "citation": "Michael Thorpe et al. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.. Leukemia research (2012 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22607959/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22555082",
      "citation": "Hannah B Trickett et al. Azacitidine-associated Sweet's syndrome.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2012 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22555082/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22550562",
      "citation": "Elena Elli et al. A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.. Mediterranean journal of hematology and infectious diseases (2012)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22550562/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22280532",
      "citation": "Massimo Breccia et al. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.. Leukemia & lymphoma (2012 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22280532/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21981697",
      "citation": "Lieke H van der Helm et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.. British journal of haematology (2011 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21981697/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21828134",
      "citation": "Thorsten Braun et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.. Blood (2011 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21828134/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21656746",
      "citation": "Rubens Costa et al. Activity of azacitidine in chronic myelomonocytic leukemia.. Cancer (2011 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21656746/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21625315",
      "citation": "M Greco et al. 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.. Mediterranean journal of hematology and infectious diseases (2011)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21625315/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21576646",
      "citation": "Guillermo Garcia-Manero et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21576646/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21537084",
      "citation": "Romain Aucagne et al. Transcription intermediary factor 1\u03b3 is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.. The Journal of clinical investigation (2011 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21537084/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21387357",
      "citation": "Murat Ozbalak et al. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.. Hematological oncology (2012 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21387357/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "20507806",
      "citation": "R Edlin et al. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.. Health technology assessment (Winchester, England) (2010 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20507806/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "20451404",
      "citation": "John F Seymour et al. Effects of azacitidine compared with conventional care regimens in elderly (\u2265 75 years) patients with higher-risk myelodysplastic syndromes.. Critical reviews in oncology/hematology (2010 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20451404/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "20064151",
      "citation": "Bart L Scott et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.. British journal of haematology (2010 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20064151/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "19911860",
      "citation": "Gillian M Keating Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.. Drugs (2009)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19911860/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "19638460",
      "citation": "Maria Teresa Voso et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.. Clinical cancer research : an official journal of the American Association for Cancer Research (2009 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19638460/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "19430863",
      "citation": "Faheem Ahmed et al. Therapy related CMML: a case report and review of the literature.. International journal of hematology (2009 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19430863/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "18179966",
      "citation": "Elizabeth A Griffiths et al. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.. Seminars in hematology (2008 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18179966/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17881052",
      "citation": "P W Wijermans et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).. Leukemia research (2008 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17881052/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17219444",
      "citation": "Ahmed Aribi et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.. Cancer (2007 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17219444/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "16955510",
      "citation": "Alfonso Quintas-Cardama et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.. Cancer (2006 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16955510/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "16882708",
      "citation": "Hagop Kantarjian et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (2007 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16882708/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "12599231",
      "citation": "Marcos de Lima et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.. Cancer (2003 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12599231/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "9922042",
      "citation": "M Beran et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia & lymphoma (1998 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9922042/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "8839838",
      "citation": "M Beran et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (1996 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8839838/",
      "drug": "azacitidine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    }
  ],
  "decitabine": [
    {
      "pmid": "40671491",
      "citation": "Bradley Rockwell et al. Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.. Haematologica (2025 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40671491/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "40524338",
      "citation": "Michael R Savona et al. Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.. British journal of haematology (2025 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40524338/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "40453133",
      "citation": "Patricia L Kropf et al. A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.. Blood neoplasia (2025 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40453133/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "40415500",
      "citation": "Jowan Al-Nusair et al. Nodal Mature Plasmacytoid Dendritic Cell Proliferation in a Patient With Chronic Myelomonocytic Leukemia: A Diagnostic Mimic of Blastic Plasmacytoid Dendritic Cell Neoplasm.. Journal of investigative medicine high impact case reports (2025)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40415500/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "40164584",
      "citation": "Alex Bataller et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.. Blood cancer journal (2025 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40164584/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "40051275",
      "citation": "Guillermo Garcia-Manero et al. A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.. Future oncology (London, England) (2025 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40051275/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "39734743",
      "citation": "Anthony Crymes et al. Acute Myeloid Leukemia (AML) With T-Cell Differentiation Arising From Chronic Myelomonocytic Leukemia (CMML).. Case reports in hematology (2024)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39734743/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "39300079",
      "citation": "Hagop Kantarjian et al. Current status and research directions in acute myeloid leukemia.. Blood cancer journal (2024 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39300079/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "39024804",
      "citation": "Kaiyue Wang et al. Targeting DNA methyltransferases for cancer therapy.. Bioorganic chemistry (2024 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39024804/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "40454402",
      "citation": "Samuel Urrutia et al. Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML.. Blood neoplasia (2024 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40454402/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "38450850",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.. American journal of hematology (2024 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38450850/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "38387931",
      "citation": "Xiao Li et al. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].. Zhongguo shi yan xue ye xue za zhi (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38387931/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "38316134",
      "citation": "Sarit Assouline Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia.. The Lancet. Haematology (2024 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38316134/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "38316133",
      "citation": "Alex Bataller et al. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.. The Lancet. Haematology (2024 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38316133/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "38135371",
      "citation": "Guillermo Garcia-Manero et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.. The Lancet. Haematology (2024 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38135371/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37994196",
      "citation": "Andrew M Brunner et al. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.. American journal of hematology (2024 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37994196/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37754496",
      "citation": "John Paul Yun et al. Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada.. Current oncology (Toronto, Ont.) (2023 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37754496/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37546162",
      "citation": "Anwarul Islam An unusual response to 5-azacitidine by a patient with chronic myelomonocytic leukemia.. Clinical case reports (2023 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37546162/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37495538",
      "citation": "Tomoyuki Saga et al. Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study.. Internal medicine (Tokyo, Japan) (2024 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37495538/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37409458",
      "citation": "Xiaofei Song et al. Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases.. Platelets (2023 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37409458/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "37341641",
      "citation": "David Levitz et al. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.. Clinical cancer research : an official journal of the American Association for Cancer Research (2023 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37341641/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36845813",
      "citation": "Shekhar Gurung et al. Chronic myelomonocytic leukemia in a 72-year-old male from Nepal: A case report.. Annals of medicine and surgery (2012) (2023 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36845813/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36801588",
      "citation": "Tugcan Alp Kirkizlar et al. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.. Leukemia research (2023 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36801588/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36653885",
      "citation": "Ankur Sheel et al. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report.. Cardio-oncology (London, England) (2023 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36653885/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36479336",
      "citation": "Unknown authors Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes.. Australian prescriber (2022 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36479336/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36455187",
      "citation": "Raphael Itzykson et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36455187/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36338706",
      "citation": "Kefeng Shen et al. Inherited heterozygous Fanconi anemia gene mutations in a therapy-related CMML patient with a rare . Frontiers in oncology (2022)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36338706/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "36150563",
      "citation": "Faezeh Darbaniyan et al. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.. Experimental hematology (2022 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36150563/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35707788",
      "citation": "Xinhui Zheng et al. Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis.. Global medical genetics (2022 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35707788/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35656122",
      "citation": "Priyanka Lakshmanan et al. Central Diabetes Insipidus Induced by Acute Myeloid Leukemia with DNMT3A Mutation.. Case reports in endocrinology (2022)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35656122/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "35093134",
      "citation": "Nicholas J Short et al. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.. Journal of hematology & oncology (2022 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35093134/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34985762",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.. American journal of hematology (2022 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34966690",
      "citation": "Konstantinos Liapis et al. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?. Frontiers in oncology (2021)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34966690/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34687602",
      "citation": "Hagop Kantarjian et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.. The Lancet. Haematology (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34687602/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34558354",
      "citation": "Katie Xu et al. Novel agents for myelodysplastic syndromes.. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34558354/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34233332",
      "citation": "Hee Sue Park et al. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.. Acta haematologica (2021)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34233332/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "34175902",
      "citation": "Aline Renneville et al. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.. Leukemia (2021 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34175902/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33904891",
      "citation": "Anand A Patel et al. Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.. Blood advances (2021 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33904891/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33878941",
      "citation": "Pasquale Niscola et al. New landscapes in the management of myelodysplastic syndromes and chronic myelomonocytic leukemia: oral decitabine.. Future oncology (London, England) (2021 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33878941/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33869012",
      "citation": "MinMing Li et al. Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients.. Frontiers in oncology (2021)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33869012/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33853476",
      "citation": "Molly Schiffer et al. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.. Expert review of anticancer therapy (2021 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33853476/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33807279",
      "citation": "Jan Philipp Bewersdorf et al. Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).. Cancers (2021 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33807279/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33792103",
      "citation": "Douglas Tremblay et al. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.. The oncologist (2021 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33792103/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33769069",
      "citation": "David Kipp et al. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.. Future oncology (London, England) (2021 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33769069/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33709786",
      "citation": "Swapna Thota et al. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Future oncology (London, England) (2021 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33709786/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33706667",
      "citation": "Ruohao Xu et al. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33706667/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33644180",
      "citation": "Can Chen et al. Chronic myelomonocytic leukemia-associated pulmonary alveolar proteinosis: A case report and review of literature.. World journal of clinical cases (2021 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33644180/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33407852",
      "citation": "Johannes Lorenz Berg et al. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.. Clinical epigenetics (2021 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33407852/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33369023",
      "citation": "John C Molina et al. Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.. Pediatric blood & cancer (2021 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33369023/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33280448",
      "citation": "Jorge Ramos Perez et al. Emerging drugs for the treatment of chronic myelomonocytic leukemia.. Expert opinion on emerging drugs (2020 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33280448/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33275673",
      "citation": "Mrinal M Patnaik et al. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.. Hematology. American Society of Hematology. Education Program (2020 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "33255988",
      "citation": "Fabio Forghieri et al. . International journal of molecular sciences (2020 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33255988/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32896301",
      "citation": "Courtney D DiNardo et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.. The Lancet. Haematology (2020 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32896301/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32860582",
      "citation": "Sohita Dhillon Decitabine/Cedazuridine: First Approval.. Drugs (2020 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32860582/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "32285126",
      "citation": "Guillermo Garcia-Manero et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.. Blood (2020 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32285126/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31736132",
      "citation": "Mrinal M Patnaik et al. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.. American journal of hematology (2020 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31736132/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31623402",
      "citation": "Vanessa Kohl et al. Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies.. Cancers (2019 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31623402/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31559392",
      "citation": "Abhishek A Mangaonkar et al. Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.. Advances in cell and gene therapy (2019 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31559392/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31494229",
      "citation": "Yi-Geng Cao et al. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2020 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31494229/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31340618",
      "citation": "X L Zhao et al. [Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2019 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31340618/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31060979",
      "citation": "Guillermo Garcia-Manero et al. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.. The Lancet. Haematology (2019 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31060979/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "31020568",
      "citation": "Matthieu Duchmann et al. Clinical update on hypomethylating agents.. International journal of hematology (2019 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31020568/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30964202",
      "citation": "Tucker Coston et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.. American journal of hematology (2019 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30964202/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30926081",
      "citation": "Michael R Savona et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.. The Lancet. Haematology (2019 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30926081/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30579366",
      "citation": "Paola Orsini et al. Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies.. Diagnostic pathology (2018 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30579366/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "30367269",
      "citation": "Anthony M Hunter et al. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.. Current treatment options in oncology (2018 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30367269/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29878489",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.. American journal of hematology (2018 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29878489/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29731877",
      "citation": "Huan Liu et al. Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.. Oncology letters (2018 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29731877/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29728305",
      "citation": "Matthieu Duchmann et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.. EBioMedicine (2018 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29728305/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29588547",
      "citation": "Hein Than et al. Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.. Leukemia (2018 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29588547/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "29069007",
      "citation": "Yayue Gao et al. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.. Medicine (2017 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29069007/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28774880",
      "citation": "Elias Jabbour et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.. Blood (2017 Sep)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28774880/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28621841",
      "citation": "Amer M Zeidan et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.. Cancer (2017 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28621841/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28607470",
      "citation": "V Santini et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.. Leukemia (2018 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28607470/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28498370",
      "citation": "M Duchmann et al. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.. Blood cancer journal (2017 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28498370/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28370097",
      "citation": "Ana Alfonso et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.. American journal of hematology (2017 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28370097/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28359286",
      "citation": "Florian Wolff et al. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.. Cell communication and signaling : CCS (2017 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28359286/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "28102729",
      "citation": "Jia Gu et al. Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.. Cancer biology & therapy (2017 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28102729/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "27849645",
      "citation": "Ana Alfonso et al. Current management of patients with chronic myelomonocytic leukemia.. Current opinion in oncology (2017 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27849645/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "27185207",
      "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.. American journal of hematology (2016 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27185207/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26968357",
      "citation": "Guillermo Garcia-Manero et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.. The Lancet. Oncology (2016 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26968357/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26908133",
      "citation": "Jane Merlevede et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.. Nature communications (2016 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26908133/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26860635",
      "citation": "Marjan Cruijsen et al. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2016 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26860635/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "26462118",
      "citation": "Salih Subari et al. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia.. Leukemia & lymphoma (2016 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26462118/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25822018",
      "citation": "Kristen Meldi et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.. The Journal of clinical investigation (2015 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25822018/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25735917",
      "citation": "St\u00e9phanie Harel et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.. Leukemia research (2015 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25735917/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25663885",
      "citation": "Qi Deng et al. Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report.. Oncology letters (2015 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25663885/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "25555161",
      "citation": "M M Patnaik et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.. Blood cancer journal (2015 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25555161/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "24653636",
      "citation": "Hee-Jun Kim et al. A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia.. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu (2014 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24653636/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": 1,
      "patients_with_ae": 1,
      "supporting_quotes": [
        "The hearing impairment had arisen during the third cycle of decitabine.",
        "To our knowledge, this is the first case that idiopathic sudden hearing loss (SHL) occured in CMML patients during treatment with decitabine."
      ],
      "data_source_location": "PMC (partial)",
      "extraction_confidence": 1.0,
      "ae_summary": "Sudden hearing loss (SHL) occurred during the third cycle of decitabine treatment in a 73-year-old male patient with chronic myelomonocytic leukemia (CMML). This is reported as the first case of idiopathic SHL in a CMML patient treated with decitabine.",
      "has_ae_data": true
    },
    {
      "pmid": "24270737",
      "citation": "H Yang et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.. Leukemia (2014 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24270737/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "24261579",
      "citation": "D Shah et al. A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.. Haemophilia : the official journal of the World Federation of Hemophilia (2014 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24261579/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23963888",
      "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.. American journal of hematology (2013 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23963888/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23671007",
      "citation": "Ellen J B Derissen et al. Concise drug review: azacitidine and decitabine.. The oncologist (2013)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23671007/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23336938",
      "citation": "Maria Teresa Voso et al. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.. European journal of haematology (2013 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23336938/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "23262795",
      "citation": "Jun Ho Yi et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.. Annals of hematology (2013 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23262795/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22911588",
      "citation": "J C Sousa et al. Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.. Genetics and molecular research : GMR (2012 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22911588/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22615103",
      "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.. American journal of hematology (2012 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22615103/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22555082",
      "citation": "Hannah B Trickett et al. Azacitidine-associated Sweet's syndrome.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2012 May)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22555082/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "22213878",
      "citation": "Li Wang et al. [Treatment of two chronic myelomonocytic leukemia patients with Decitabine].. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2011 Jul)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22213878/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21828134",
      "citation": "Thorsten Braun et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.. Blood (2011 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21828134/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21656746",
      "citation": "Rubens Costa et al. Activity of azacitidine in chronic myelomonocytic leukemia.. Cancer (2011 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21656746/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21537084",
      "citation": "Romain Aucagne et al. Transcription intermediary factor 1\u03b3 is a tumor suppressor in mouse and human chronic myelomonocytic leukemia.. The Journal of clinical investigation (2011 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21537084/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "21425542",
      "citation": "Eric Solary et al. [Myeloproliferative/myelodysplastic syndromes].. La Revue du praticien (2010 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21425542/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "20929328",
      "citation": "Marcelo Iastrebner et al. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience.. Leukemia & lymphoma (2010 Dec)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20929328/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "20564137",
      "citation": "Elias Jabbour et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.. Cancer (2010 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20564137/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "20511166",
      "citation": "G Nicolas Batty et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.. Clinical lymphoma, myeloma & leukemia (2010 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20511166/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "18496432",
      "citation": "Michael R Hinckley et al. Generalized granuloma annulare as an initial manifestation of chronic myelomonocytic leukemia: a report of 2 cases.. The American Journal of dermatopathology (2008 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18496432/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "18179966",
      "citation": "Elizabeth A Griffiths et al. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.. Seminars in hematology (2008 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18179966/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "18055864",
      "citation": "Yasuhiro Oki et al. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.. Blood (2008 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18055864/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17881052",
      "citation": "P W Wijermans et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).. Leukemia research (2008 Apr)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17881052/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17701595",
      "citation": "David P Steensma et al. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.. Leukemia & lymphoma (2007 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17701595/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17644750",
      "citation": "Aristoteles A N Giagounidis Decitabine dosage in myelodysplastic syndromes.. Blood (2007 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17644750/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17612710",
      "citation": "Kalpana Ghoshal et al. DNA methyltransferases as targets for cancer therapy.. Drugs of today (Barcelona, Spain : 1998) (2007 Jun)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17612710/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17315156",
      "citation": "Hagop M Kantarjian et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.. Cancer (2007 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17315156/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17313156",
      "citation": "David P Steensma et al. Risk-based management of myelodysplastic syndrome.. Oncology (Williston Park, N.Y.) (2007 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17313156/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17219444",
      "citation": "Ahmed Aribi et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.. Cancer (2007 Feb)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17219444/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "17133405",
      "citation": "Hagop M Kantarjian et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.. Cancer (2007 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17133405/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "16955510",
      "citation": "Alfonso Quintas-Cardama et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.. Cancer (2006 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16955510/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "16882708",
      "citation": "Hagop Kantarjian et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (2007 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16882708/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "16464494",
      "citation": "M Daskalakis et al. Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.. Leukemia research (2006 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16464494/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "12599231",
      "citation": "Marcos de Lima et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.. Cancer (2003 Mar)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12599231/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "11529854",
      "citation": "M L\u00fcbbert et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.. British journal of haematology (2001 Aug)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11529854/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "9922042",
      "citation": "M Beran et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia & lymphoma (1998 Nov)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9922042/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "9001409",
      "citation": "P W Wijermans et al. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.. Leukemia (1997 Jan)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/9001409/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    },
    {
      "pmid": "8839838",
      "citation": "M Beran et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (1996 Oct)",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8839838/",
      "drug": "decitabine",
      "any_grade_ae_rate": null,
      "grade_3_4_ae_rate": null,
      "serious_ae_rate": null,
      "treatment_related_ae_rate": null,
      "hematologic_ae": null,
      "non_hematologic_ae": null,
      "discontinuation_rate": null,
      "dose_reduction_rate": null,
      "total_patients": null,
      "patients_with_ae": null,
      "supporting_quotes": [],
      "data_source_location": "Unknown",
      "extraction_confidence": null,
      "ae_summary": null,
      "has_ae_data": false
    }
  ]
}